Back to journals
Academic Journal

Psychiatry Research

26 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 26 psychedelic papers Blossom tracks from Psychiatry Research line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Psychiatry Research carry?

Sourced

Tracked papers by publication year; 1 earlier paper published before 2012. Click a year for the running total.

5papers published in 2022

+25% vs 2021

17 published by 2022

Browse papers→

Don't read as the journal's total output: only the 26 of 26 tracked psychedelic papers from Psychiatry Research with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Psychiatry Research publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
22
Anxiety Disorders
11
Suicidality
6
Safety & Risk Management
5
Addiction & Substance Use
4
Bipolar Disorder
4
Public Health, Prevention & Behaviour Change
4
Adolescents
3
Other
21

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Psychiatry Research cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ketamine
16
Psilocybin
6
Esketamine
2
MDMA
2
Ayahuasca
1
LSD
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Psychiatry Research has 26 tracked papers indexed in Blossom (2000–2026) from 206 authors, most often covering Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Anxiety Disorders and Major Depressive Disorder (MDD).

Published Papers

Paywallindividual

Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study

This observational study (n=90) followed outpatients with treatment-resistant depression starting intranasal esketamine, with and without comorbid borderline personality disorder, and found depressive symptoms improved over six months in both groups. People with borderline personality disorder improved faster at first, while remission rates were similar and no serious adverse events or cognitive decline were seen.

Published
Journal
Psychiatry Research
Authors
Mazzoni, F., Raffone, F., De Ciechi, A., Girone, N., Macellaro, M., Martinotti, G., Dell’Osso, B., Martiadis, V., Olivola, M.
Paywallindividual

Faster and greater antidepressant response to intravenous ketamine in bipolar compared with unipolar treatment-resistant depression: Diagnostic and sex-related findings from a naturalistic study

This observational study (n=97) examined intravenous ketamine for treatment-resistant unipolar and bipolar depression and found that symptoms improved in both groups, with faster and greater improvement in bipolar depression. Dissociative effects stayed stable overall, and sex differences in antidepressant response were not seen, although women with unipolar depression reported more dissociation at three months.

Published
Journal
Psychiatry Research
Authors
Carmellini, P., Fagiolini, A., Pinzi, M., Magno, M., Martella, D., Nicchi, L., Rescalli, M. B., Tarantino, F., Tinturini, R., Scheggi, S., Gualtieri, G., Cuomo, A.
Open Accessmeta

Psychedelics as a potential treatment for borderline personality disorder: A narrative review

This narrative review (s=22) examined studies of ketamine, esketamine and psilocybin in people with borderline personality disorder and found early evidence that they may help core symptoms and social and work functioning. It also noted that patients with BPD are often excluded from research because of safety concerns, especially around suicide and substance misuse.

Published
Journal
Psychiatry Research
Authors
Artna, E., Sandhu, G., Chisamore, N., Lipsitz, O., Kaczmarek, E. S., Johnson, D. E., Rosenblat, J. D., Sediqzadah, S.
Paywallmeta

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

This pooled analysis (s=9) examined how much session facilitators shape participants' acute subjective effects across psilocybin studies involving 298 participants and 60 facilitators, finding that facilitator influence was negligible in healthy volunteers (0.8% of variance) but clinically meaningful in patient samples (13.6%), comparable to or exceeding typical therapist effects seen in conventional psychotherapy.

Published
Journal
Psychiatry Research
Authors
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia-Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., Nayak, S. M.
Open Accessindividual

IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital

This longitudinal study (n=71) examines five years of real-world clinical data on the use of IV low-dose ketamine alongside standard care for outpatients with depression (MDD & TRD). Results indicate a significant reduction in depressive symptoms and suicide ideation by treatment endpoint, with 55% of patients responding to treatment. Side effects were transient and mild for 78% of patients, with a dropout rate of 11%. Multivariate analysis suggests that demographic variables did not impact treatment efficacy or tolerability.

Published
Journal
Psychiatry Research
Authors
Gutierrez, G., Kang, M. J. Y., Vasquez, G.
Paywallindividual

Anti-suicidal effects of IV ketamine in a real-world setting

This community-based study (n=295) examined the impact of intravenous ketamine treatment on suicidality. Using growth mixture modelling, three trajectory groups were identified: one with moderate baseline scores showing gradual improvement (n=170, 57.6%), another with severe baseline scores showing no improvement (n=63, 21%), and a third with rapid improvement (n=62, 21%). Among clinical and demographic variables, only higher scores on active thoughts of death and/or plan predicted a lack of benefit from treatment for those with severe baseline CHRT-SR scores. The findings support ketamine's potential effectiveness in addressing suicidality in a proportion of patients.

Published
Journal
Psychiatry Research
Authors
O'Brien, B., Lee, J., Kim, S., Nandra, G. S., Pannu, P., Tamman, A. J. F., Amarneh, D., Swann, A. C., Murphy, N., Averill, L. A., Jha, M. K., Mathew, S. J.

Quick Facts

Papers Indexed
26
h-Index
187
Open Access
No
Publisher
Elsevier
Country
Ireland
Website
Visit